Fred M. Powell - Jan 1, 2025 Form 3 Insider Report for LAVA Therapeutics NV (LVTX)

Role
Chief Financial Officer
Signature
/s/ Amy Garabedian, Attorney-in-Fact
Stock symbol
LVTX
Transactions as of
Jan 1, 2025
Transactions value $
$0
Form type
3
Date filed
1/2/2025, 09:20 AM
Previous filing
May 26, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LVTX Common Shares 65K Jan 1, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LVTX Share Options (Right to Buy) Jan 1, 2025 Common Shares 195K $4.38 Direct F1
holding LVTX Share Options (Right to Buy) Jan 1, 2025 Common Shares 121K $1.59 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 48,750 of the shares underlying the option vested on November 1, 2023 and the remainder vests in 36 equal monthly installments beginning on December 1, 2023, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date.
F2 The shares underlying the option vest in 48 equal monthly installments beginning on February 19, 2024, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date.